Ovarian Cancer (update of OV28)
Project summary
Ovarian cancer accounts for 6% of all female cancer deaths and is the cause of more deaths in women than all other gynaecological malignancies combined. Measuring QoL to evaluate the treatment options of different types of cancer are crucial. Since the development of EORTC QLQ OV28 in 1997, more treatment options for ovarian cancer have become available and other side-effects have been reported. Therefore, an updated questionnaire will be developed.
Achievements
The literature review to identify studies using the existing questionnaire and new questionnaires with issues that were not included in the existing questionnaire has been completed.
Activation of collaborating sites.
The investigator package has been sent out and collaborators are currently applying for ethical approval or are already conducting the interviews with patients and HCPs.
Future plans
Interviews with patients and HCPs started with the aim of completing by Spring 2025.
The report for phase I of the study will be written up.
An Amendment for phase II of the study will be submitted.
For patients
When evaluating the impact of an illness such as cancer, one of the most important areas to consider is the effect on quality of life. In this study, a literature review and interviews with patients and health care professionals will be conducted to help us understand the impact of ovarian cancer on the quality of life of patients. Due to the rising number of new treatments, the question is if the existing questionnaire to assess the quality of life in patients diagnosed with ovarian cancer should be updated.